Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results

Cancer Treatment Reviews

Volumn 38, Issue 2, 2012, Pages 120-126

  Aapro, Matti ^a   Finek, Jindrich ^b  

^a Multidisciplinary Institute of Oncology   (Switzerland)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Metastatic breast cancer; Oral chemotherapy; Oral vinorelbine

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CENTRAL VENOUS CATHETER; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREMEDICATION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SOCIAL BEHAVIOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 84856328530     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.005     Document Type: Review

References (55)

1. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006, 33(Suppl. 2):S2-S5.
2. Cardoso F., Senkus-Konefka E., Fallowfield L., et al. Locally-recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v15-v19.
3. Pajk B., Cufer T., Canney P., et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008, 17:180-185.
4. Findlay M., Von Minckwitz G., Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008, 19:212-222.
5. Liu G., Franssen E., Fitch M., et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
6. James R., Barni S., Fischer von Weikerstahl L., et al. Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: TAMINO, an international time and motion audit. Eur J Cancer Supplements 2009, 7:2. (abstract 3612).
7. Fellous A., Ohayon R., Vacassin T., et al. Biochemical effects of vinorelbine on tubulin and associated proteins. Semin Oncol 1989, 16(Suppl. 4).
8. Cros S., Wright M., Morimoto M., et al. Experimental antitumor activity of vinorelbine. Semin Oncol 1989, 16(Suppl. 4).
9. Goa K., Faulds D. Vinorelbine: a review of its pharmacological properties and clinical use in cancer chemotherapy. Drug Aging 1994, 5(3):200-234.
10. Marty M., Fumoleau P., Adenis A., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumours. Ann Oncol 2001, 12:1643-1649.
11. Kajita J., Kuwabara T., Kobayashi H., et al. CYP3A4 is mainly responsible for the metabolism of vinorelbine in human liver microsomes. Drug Metab Dispos 2000, 28:1121-1127.
12. Freyer G., Delozier T., Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003, 21:35-40.
13. Amadori D., Koralewski P., Tekiela A., et al. Efficacy and safety of oral vinorelbine in first-line metastatic breast cancer. Eur J Cancer 2001, 37(Suppl. 6). (abstract 713).
14. Trillet Lenoir V., Sommer H., Delozier T., et al. Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Cancer Supplements 2004, 2:3. (abstract 279).
15. Pluschnig U., Bartsch R., Gampenrieder S., et al. Oral vinorelbine in metastatic breast cancer: the Vienna experience. Ann Oncol 2008, 19(Suppl. 8). (abstract 160).
16. Blancas I., Morales S., Diaz N., et al. Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol 2010, 28:15S. (abstract 1090).
17. Mansour M, Haddad N. Phase II study of single agent oral vinorelbine as a first line chemotherapy for metastatic breast cancer patients previously treated with adjuvant anthracyclines and/or taxanes. Proc 21st International Congress on Anti-Cancer Treatment, 2010 (abstract 627).
18. Addeo R., Faiola V., Montella L., et al. A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: a phase II trial. J Clin Oncol 2009, 27:15S. (abstract 1085).
19. Chan A., Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer 2009, 45:2253-2265.
20. Sawada N, Fujimoto-Ouchi K, Ishikawa T, et al. Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002 (abstract 5388).
21. Nolé F., Catania C., Sanna G., et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006, 17:322-329.
22. Kellokumpu-Lehtinen P., Sunela K., Lehtinen I., et al. For the Finnish Breast Cancer Group. A phase I study of an all oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 2006, 7:401-405.
23. Anton A., Lluch A., Casado A., et al. Phase I-II study of oral vinorelbine and capecitabine in metastatic breast cancer: results of the phase I trial. Anticancer Res 2010, 30:2255-2261.
24. Tubiana Mathieu N., Bougnoux P., Becquart D., et al. All-oral combination of vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international phase II trial. Brit J Cancer 2009, 101:232-237.
25. Nolé F., Crivellari D., Mattioli R., et al. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009, 64:673-680.
26. Finek J., Holubec L., Svoboda T., et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009, 29:667-670.
27. Delcambre C., Veyret C., Levy C., et al. A phase I/II study of capecitabine combined with oral vinorelbine as first or second line therapy in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2005, 94:S67. (abstract 1081).
28. Jones A., O'Brien M., Sommer H., et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 2010, 65:755-763.
29. Lorusso V., Spada M., Giampaglia M., et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 2006, 17(Suppl. 7):vii 15-vii 17.
30. Campone M., Dobrovolskaya N., Tjulandin S., et al. A 3-arm randomised phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo, X in sequence versus docetaxel (D) plus X in patients with metastatic breast cancer previously treated with anthracyclines. Eur J Cancer Supplements 2009, 7:2. (abstract 5000).
31. Serin D., Verrill M., Jones A., et al. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentric phase II study. Brit J Cancer 2005, 92:1989-1996.
32. Campone M., Blasinska-Morawiec M., Tekiela A., et al. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 2008, 63:937-943.
33. Ardavanis A., Kountourakis P., Maliou S., et al. Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline and taxane pretreated breast cancer. Anticancer Res 2007, 27:2989-2992.
34. Delva R., Pienkowski T., Tubiana N., et al. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 2007, 59:703-709.
35. Bonneterre J., Campone M., Koralewski P., et al. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 2007, 60:365-373.
36. Addeo R., Faiola V., Guarrasi R., et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women >65 years of age. Cancer Chemother Pharmacol 2008, 62:285-292.
37. Lorusso V., Leo S., Ciccarese M., et al. A multicenter randomized phase II study of nonpegylated liposomal doxorubicin plus vinorelbine versus nonpegylated liposomal doxorubicin plus cyclophosphamide as first-line in locally advanced breast cancer or metastatic breast cancer: safety results. J Clin Oncol 2009, 27:15S. (abstract 1116).
38. Addeo R., Caraglia M., Montella L., et al. Metronomic oral vinorelbine, temozolomide after whole brain radiotherapy for the treatment of breast cancer patients with brain metastases. A phase II study. Eur J Cancer Supplements 2008, 6:7. (abstract 411).
39. Garcia Palomo A., Sommer H., Malamos N., et al. First results of an international, retrospective international study of metastatic breast cancer patients treated with oral vinorelbine-based chemotherapy. Eur J Cancer Supplements 2010, 8:3. (abstract 474).
40. Pegram M., Konecny G., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Nat Can Inst 2004, 96:739-749.
41. Bernardo G., Palumbo R., Bernardo A., et al. Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: final results of an extended phase II trial. Eur J Cancer Supplements 2006, 6:7. (abstract 168).
42. Bartsch R., Wenzel C., Altorjai G., et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007, 102(3):375-381.
43. Heinemann V, Di Gioia D, Vehling-Kaiser U, et al. A prospective, multicenter phase II study of oral and intravenous vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 2010. doi: doi:10.1093/annonc/mdq409.
44. Illarramendi J., Blancas I., Bueso P., et al. Oral vinorelbine in combination with trastuzumab in metastatic breast cancer: data on efficacy, safety when administered in first or second line setting. J Clin Oncol 2010, 28:15S. (abstract e11508).
45. Petruzelka L., Ganju V., Becquart D., et al. Phase II study of the combination of oral vinorelbine, capecitabine and trastuzumab in HER2-positive metastatic breast cancer: recent analysis of the results with a median follow-up of 44months. J Clin Oncol 2010, 28:15S. (abstract 1077).
46. Palumbo R., Bernardo A., Strada M., et al. Triple combination of 3-weekly trastuzumab plus oral vinorelbine and capecitabine as first-line treatment in HER2- positive metastatic breast cancer: an active and well-tolerated regimen that allows patient compliance. Eur J Cancer Supplements 2009, 7(2). (abstract 5081).
47. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced HER2-positive breast cancer: the HERNATA study. J Clin Oncol 2010. doi: doi:10.1200/JCO.2010.32.590.
48. Locatelli M., Curigliano L., Fumagalli R., et al. Bevacizumab, oral chemotherapy for patients with lymphangitic breast cancer: a phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. J Clin Oncol 2009, 27:15S. (abstract 1031).
49. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2010.
50. Beslija S., Bonneterre J., Burstein H., et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-1785.
51. Von Minckwitz G. Evidence-based treatment of metastatic breast cancer. 2006 recommendations by the AGO breast commission. Eur J Cancer 2006, 42:2897-2908.
52. NICE Clinical Guideline 81: advanced breast cancer: diagnosis and treatment. February 2009.
53. Cardoso F., Bedard P., Winer E., et al. International guidelines for management of metastatic breast cancer: combination or sequential single-agent chemotherapy. J Natl Cancer Inst 2009, 101:1174-1181.
54. Coates A., Stockler M., Wilcken N. Controversies in metastatic breast cancer: optimal duration of chemotherapy. ASCO Educational Book 2003, 119-121.
55. Gennari A., Sormani M., Nanni O., et al. Impact of first-line chemotherapy duration in metastatic breast cancer: a systematic review. J Clin Oncol 2010, 28:15S. (abstract 1023).